ClinicalTrials.gg
RecruitingNCT07185230Updated Dec 9, 2025

Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions

An interventional study of Atosiban and Placebo Control in Infertility, sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
792
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.

Planned enrollment
23rd of 107
792 · median 248
Started
2025
with 13 others
No phase
65 of 139
22 open now
Primary completion
2027-06
later than 19 of 40 live
Registered
125th of 139
by date
Lead sponsor
3 of 139
Northwest Women's and Children's Hospital, Xi'an, Shaanxi

Among the 139 studies in Infertility with a site in China, this one is the 23rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 14 that started in 2025, is one of 65 with no phase, reaches primary completion later than 19 of the 40 other live ones, and was the 125th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Infertility with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy of atosiban in patients with previous pregnancy failure and abnormal uterine contractions during the peri-embryo transfer period in assisted reproductive technology. The main questions it aims to answer are:

  • Does the use of atosiban in patients with a history of implantation failure and abnormal uterine contractions affect the live birth rate in single blastocyst transfer cycles (fresh or frozen-thawed embryo transfer)?
  • Evaluate the differences in efficacy of atosiban regarding perinatal complications and neonatal outcomes, as well as differences in safety concerning miscarriage rates and ectopic pregnancy rates.

Researchers will compare atosiban with placebo (a similar substance containing no active medication) to determine whether atosiban is effective in improving live birth rates from single blastocyst transfer cycles (fresh or frozen-thawed embryo transfer) in patients with a history of implantation failure and abnormal uterine contractions.

  • Participants allocated to the Atosiban group will be administered Atosiban (37.5 mg/5 mL, Tractocile®, Ferring Pharma, Geneva, Switzerland) as an intravenous (IV) bolus of 6·75 mg/0.9 mL in 1 minute at 30 minutes prior to the ET procedure, followed by an IV infusion at a rate of 18 mg/h for 1 hour; after 1 hour, the dose of Atosiban will be reduced to 6 mg/h, with a total dose of 37.5 mg. Participants allocated to the placebo group will receive identical-looking saline infusions for the same duration.
  • One hour post-embryo transfer, all randomized participants will be invited to have a reevaluation of uterine wave patterns via ultrasound, performed by the same examiner.
  • Women who had a clinical pregnancy will be subsequently contacted by nurses to document pregnancy events and outcomes at 12 and 24 weeks of gestation, completion of pregnancy, with a follow-up approximately 6 weeks post-delivery. Those participants who had a negative pregnancy test will not be followed up any further as part of this trial.
03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Atosiban
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Participants/eligibility criteria

Infertile women who fulfill all of the following inclusion criteria, based on the results and findings of the Atosiban 1 study are eligible for participation:

  1. Scheduled for single blastocyst-stage embryo transfer, either in a fresh or frozen transfer cycle;
  2. Have a history of one or more episodes of implantation failures in previous embryo transfer cycles;
  3. Age between 20 and 40 years (inclusive);
  4. Exhibit abnormal uterine peristalsis on transvaginal ultrasound performed on the morning of the scheduled blastocyst transfer, defined as either: high-frequency peristalsis (>4 contractions per minute), or a negative wave pattern (fundus-to-cervix direction) at any frequency.
  5. Each woman could only participate in one transfer cycle.

Exclusion criteria

  1. Immunologic or endocrine disorders including thyroid dysfunction, antiphospholipid syndrome, hyperprolactinemia and other severe systematic diseases (e.g., hypertension, diabetes, etc.)
  2. Uterine malformations (e.g., intrauterine adhesions; unicornuate, bicornuate or septate uterus);
  3. Untreated hydrosalpinx or endometrial polyp;
  4. Cycles that included in-vitro maturation or oocyte donation;
  5. Prior participation in Atosiban 1 study;
  6. Current participation in any other clinical trial;
  7. Inability to provide to the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
792 participants (estimated)

Study arms

  • Experimental
    Atosiban group

    Participants allocated to the Atosiban group will be administered Atosiban

    Drug: Atosiban

  • Placebo comparator
    Placebo group

    Participants allocated to the placebo group will receive saline infusions.

    Drug: Placebo Control

Interventions

  • Participants allocated to the Atosiban group will be administered Atosiban (37.5 mg/5 mL, Tractocile®, Ferring Pharma, Geneva, Switzerland) as an intravenous (IV) bolus of 6·75 mg/0.9 mL in 1 minute at 30 minutes prior to the ET procedure, followed by an IV infusion at a rate of 18 mg/h for 1 hour; after 1 hour, the dose of Atosiban will be reduced to 6 mg/h, with a total dose of 37.5 mg.

  • DrugPlacebo Control

    Participants allocated to the placebo group will receive identical-looking saline infusions for the same duration.

06

What researchers measure

Primary outcomes

  1. Live birth

    Live birth is defined as the delivery of at least one newborn who exhibits any sign of life.

    Time frame: After 24 weeks of gestation

Secondary outcomes

  1. Biochemical pregnancy

    Biochemical pregnancy is defined as serum beta-human chorionic gonadotropin β-hCG\> 10 IU/L 12 days after blastocyst transfer.

    Time frame: 12 days after blastocyst transfer

  2. Clinical pregnancy

    Clinical pregnancy is defined as observed gestational sac or definitive clinical signs of pregnancy observed at ultrasonography (including clinically documented ectopic pregnancy)

    Time frame: 6-8 weeks after blastocyst transfer.

  3. Ongoing pregnancy

    Ongoing pregnancy is defined as the presence of a gestational sac and fetal heartbeat after 12 weeks of gestation.

    Time frame: After 12 weeks of gestation

  4. Miscarriage

    Miscarriage is defined as spontaneous loss of an intrauterine pregnancy prior to 20 completed weeks of gestational age.

    Time frame: before 20 weeks of gestation.

  5. Stillbirth

    Stillbirth is defined as the death of a fetus prior to the complete expulsion or extraction from its mother after 20 completed weeks of gestational age including deaths during labor.

    Time frame: after 20 weeks of gestation

  6. Ectopic pregnancy

    Ectopic pregnancy is defined as a pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization, or histopathology.

    Time frame: After 4 to 6 weeks of embryo transfer

  7. Multiple pregnancy

    Multiple pregnancy is defined as a pregnancy with two or more gestational sacs or positive heart beats at 7 weeks of gestation.

    Time frame: 7 weeks of gestation

  8. Gestational diabetes mellitus

    Newly diagnosed diabetes or gestational diabetes at 28 weeks of pregnancy confirmed by 75 g oral glucose tolerance test.

    Time frame: At 28 weeks of pregnancy

  9. hypertensive disorders of pregnancy

    Time frame: From 20 weeks of gestation up to at birth

  10. preterm birth

    Delivery of a fetus at less than 37 and more than 28 weeks gestational age

    Time frame: At birth

  11. low birth weight

    Weight of baby born \< 2500 g

    Time frame: At birth

  12. Very low birth weight

    Weight of baby born \< 1500 g

    Time frame: At birth

  13. high birth weight

    Weight of baby born \> 4000 g

    Time frame: at birth

  14. large for gestational age

    large for gestational age is defined as birth weight greater than 90th percentile for gestation, based on standardised ethnicity-based charts

    Time frame: at birth

  15. small for gestational age

    small for gestational age is defined as less than 10th percentile for gestational age at delivery based on standardised ethnicity-based charts.

    Time frame: at birth

  16. Early neonatal death

    Early neonatal death refers to death of a live born baby within 7days of birth

    Time frame: within 7days of birth

  17. Congenital anomaly

    Any congenital anomalies detected in baby born

    Time frame: Birth to first year of life

07

Study locations

1 of 1 sites recruiting
  • Center for Reproductive Medicine, Northwest Women's and Children's Hospital
    Xi'an, Shaanxi 710003, China
    Recruiting
08

References and documents

Publications

  • Cai H, Li W, Mol BWJ, Liu D, Lei D, Ran X, Zhang D, Xue X, Gao L, Shi J. Randomised, triple-blind, placebo-controlled trial of atosiban in women with previous embryo implantation failure and abnormal uterine contractions undergoing single blastocyst-stage embryo transfer: a study protocol. BMJ Open. 2026 Jun 2;16(6):e114029. doi: 10.1136/bmjopen-2025-114029. PubMed 42229962 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.

Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 18 months is below that.

Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 22, 2025
StartActual
Dec 6, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185230
Lead sponsor
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Responsible party
He Cai (Principal investigator, Northwest Women's and Children's Hospital, Xi'an, Shaanxi) — Principal investigator
First posted
Sep 22, 2025
Start date
Dec 6, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Dec 9, 2025

Study contacts

He Cai
Contact
caihe@bjmu.edu.cn
13581613908
Juanzi Shi, Doctor
study chair · Center for Reproductive Medicine, Northwest Women's and children's Hospital, Xi'an, shaanxi. china

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atosiban

Start the discussion